DNA Repair and Prostate Cancer: A Field Ripe for Harvest.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32636098.
- Also identified by DOI 10.1016/j.eururo.2020.06.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future.
Medical subject headings
- DNA Repair
- Poly(ADP-ribose) Polymerase Inhibitors
- Prostatic Neoplasms